$CDNA

Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.

ARK ETFs sold 501,466 Roblox (RBLX) shares for $18.89M and 203,242 10X Genomics (TXG) shares for $11.31M. They bought 55,548 Broadcom (AVGO) shares for $21.11M, 60,805 Cloudflare (NET) shares for $18.32M, and 78,756 Cerebras (CBRS) shares for $17.33M. Other trades included Rocket Lab (RKLB), Ionis (IONS), CareDx (CDNA), and Securitize (SECZ).

CareDx, Inc. said it received an amended Schedule 13G/A from Baron Capital Group, Inc., BAMCO, Inc., Baron Capital Management, Inc., and Ronald Baron. The filing reports shared beneficial ownership of 1,937,326 CareDx common shares, or 3.75% of the class, down to 5% or less, with shared voting and dispositive power.

CareDx (CDNA) reported Q2 2026 revenue of $131.95M and net income of $110.64M, reversing a prior-year loss. It raised its full-year 2026 revenue outlook to $490–500M, completed a $50M buyback, and filed a $80.3M shelf for ESOP shares. The article links results to Medicare LCD frequency limits starting Aug. 30, 2026.

Baron Capital’s Baron Discovery Fund Q2 2026 investor letter said the fund rose 19.08% (Institutional Shares) in the quarter, lagging the Russell 2000 Growth Index. It highlighted CareDx (NASDAQ:CDNA), citing a CMS MolDX draft LCD that could limit reimbursement, and said the fund increased its position at $11 to $12. CareDx closed at $47.23 on Aug. 11, 2026, and reported 1Q26 revenues up 39% YoY and volumes up 17% YoY.

CareDx (CDNA) reported Q2 2026 results showing a shift from a prior net loss to net income of $110.64 million, with higher year-over-year revenue and raised full-year guidance, according to the company. The article cites a sharp share-price rise and a fair value estimate of $28 versus a $47.07 close, implying overvaluation.

CareDx, Inc. reported that independent chairman Michael Goldberg sold about $2.1m of shares at $47.06 each, cutting his stake by 24%. The article says this was the largest insider sale in the past 12 months, with no insider buys recorded. It notes insiders hold about 4.6% of the company.

Goldberg Michael sold 44,700 shares of CareDx, Inc. (CDNA) at $47.06 ($2.10M total) on 2026-08-04.

Bickerstaff George sold 20,000 shares of CareDx, Inc. (CDNA) at $46.28 ($0.93M total) on 2026-08-05.

COURNOYER CHRISTINE sold 16,000 shares of CareDx, Inc. (CDNA) at $46.94 ($0.75M total) on 2026-08-04 under a Rule 10b5-1 trading plan.